Krystal Biotech KRYS
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Krystal Biotech (KRYS) Core Market Data and Business Metrics
Latest Closing Price
$174.58Price-Earnings Ratio
98.08Total Outstanding Shares
28.81 Million SharesDividend
No dividendSIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
2100 Wharton Street, Pittsburgh, PA, 15203
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 275,333 Shares | 9.81 | 3/14/2025 | 2,701,192 Shares |
| 361,888 Shares | 7.63 | 2/28/2025 | 2,761,745 Shares |
| 200,702 Shares | 15.88 | 2/14/2025 | 3,186,586 Shares |
| 205,479 Shares | 14.66 | 1/31/2025 | 3,011,606 Shares |
| 289,740 Shares | 11.22 | 1/15/2025 | 3,251,603 Shares |
| 302,873 Shares | 11.13 | 12/31/2024 | 3,369,689 Shares |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $725,000 |
| Net Cash Flow From Financing Activities | $27.20 Million |
| Exchange Gains/Losses | $-4,000 |
| Net Cash Flow From Investing Activities | $-89.82 Million |
| Net Cash Flow From Financing Activities, Continuing | $27.20 Million |
| Net Cash Flow From Operating Activities | $63.34 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Income Tax Expense/Benefit | $5.03 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Diluted Average Shares | $89.20 Million |
| Net Income/Loss Attributable To Parent | $52.37 Million |
| Income/Loss From Continuing Operations Before Tax | $57.40 Million |
| Costs And Expenses | $184.12 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $54.27 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $54.27 Million |
| Other Comprehensive Income/Loss | $54.27 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Current Assets | $106.28 Million |
| Noncurrent Assets | $269.15 Million |
| Other Non-current Assets | $112.56 Million |
| Liabilities | $96.47 Million |
| Noncurrent Liabilities | $6.95 Million |
| Current Liabilities | $89.53 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||